FindTrial
Sign In

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers

An Open Study To Estimate The Plasma Pharmacokinetics Of PF-00241939 Administered Via Oral Inhalation Using Dry Powder Inhalers

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01181700
Enrollment
42
Registered
2010-08-13
Start date
2010-10-31
Completion date
2011-01-31
Last updated
2011-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pharmacokinetics

Brief summary

The purpose of this study is to investigate the time course of PF-00241939 concentrations in the blood following dosing by oral inhalation using dry powder inhalers.

Interventions

DRUGTreatment A

PF-00241939 300 ug using inhaler A

DRUGTreatment B

PF-00241939 300 ug using inhaler A

DRUGTreatment C

PF-00241939 300 ug using inhaler A

DRUGTreatment D

PF-00241939 300 ug using inhaler B

DRUGTreatment E

PF-00241939 300 ug using inhaler B

DRUGTreatment F

PF-00241939 300 ug using inhaler B

DRUGTreatment G

PF-00241939 300 ug using inhaler B

Sponsors

Pfizer
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy male and/or female subjects between the ages of 21 and 55 years. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).

Exclusion criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * Pregnant or nursing females. * A positive urine drug screen.

Design outcomes

Primary

MeasureTime frame
Plasma pharmacokinetic parameters: AUClast and Cmax.36 hours

Secondary

MeasureTime frame
Plasma pharmacokinetic parameters: AUC24, AUCinf, Tmax and half-life.36 hours

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026